NEMOURS CHILDRENS HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $4.6M
- Transactions
- 1,307
- Companies
- 40
- Average per transaction
- $3,543
Who reported the payments
| Biomarin Pharmaceutical Inc. | $792,327 |
| Ultragenyx Pharmaceutical Inc. | $487,437 |
| AbbVie | $389,376 |
| Hoffmann-la Roche Limited | $358,588 |
| Immedica Pharma US, Inc. | $273,763 |
| Genentech, Inc. | $231,737 |
| Ascendis Pharma Endocrinology Inc | $214,977 |
| Masimo Corporation | $200,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | $191,092 |
| Regeneron | $153,082 |
| E.r. Squibb & Sons, L.L.C. | $144,765 |
| Astrazeneca UK Limited | $123,054 |
| Albireo Pharma, Inc. | $111,052 |
| Insulet Corporation | $92,425 |
| Janssen Research & Development, LLC | $80,872 |
| Jazz Pharmaceuticals Inc. | $73,800 |
| Merck | $62,825 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $58,782 |
| Harmony Biosciences LLC | $57,150 |
| Teva Pharmaceuticals USA, Inc. | $51,197 |
| Aurinia Pharma U.S., Inc. | $50,878 |
| UCB SA | $50,441 |
| Swedish Orphan Biovitrum AB | $41,621 |
| Springworks Therapeutics, Inc. | $37,860 |
| Antares Pharma, Inc. | $34,191 |
| Astellas Pharma Global Development | $27,509 |
| Mirum Pharmaceuticals, Inc. | $26,727 |
| Vapotherm Inc | $25,318 |
| F. Hoffmann-la Roche AG | $23,093 |
| Incyte Corporation | $22,747 |
| Philips North America LLC | $19,590 |
| Sobi, Inc | $14,515 |
| Global Blood Therapeutics, Inc. | $13,439 |
| Kyowa Kirin, Inc. | $11,500 |
| Daiichi Sankyo Inc. | $10,000 |
| Mannkind Corporation | $9,978 |
| Med-el Corporation | $9,090 |
| Chiesi USA, Inc. | $7,250 |
| UCB Biosciences Inc. | $6,300 |
| Stryker | $6,295 |